In August 2024, Lupin introduced Doxorubicin Hydrochloride Liposome Injection, its generic cancer treatment drug, in the United States.
In June 2024, Teva Pharmaceuticals, Inc., a U.S. subsidiary of Teva Pharmaceutical Industries Ltd., launched an authorized generic of Victoza (liraglutide injection 1.8mg), in the U.S.
In June 2024, an approved generic of Victoza®1 (liraglutide injection 1.8 mg) was launched in the US, stated Teva Pharmaceuticals, Inc., a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. Through April 2024, Victoza® pulled in $1.656 billion in yearly revenue.
In June 2024, to treat acute adult patients' cases of hereditary angioedema, Alembic Pharmaceuticals Ltd. declared that it had received final approval from the US health authority for its generic Icatibant injectable.
In May 2024, pharma major Cipla announced on Wednesday that the US Health Department had approved the company to market a generic medicine that is used to treat acromegaly and other diseases. The Mumbai-based medicine maker announced in a release that it had received final approval from the U.S. Food and Medicine Administration (USFDA) to market Lanreotide injections in different strengths.
In February 2024, Novo Holdings, which is under the Novo Nordisk Foundation, bought Catalent for USD 16.5 billion. The deal is one of Novo Holdings' plans to leverage its Wegovy cash and increase its manufacturing capacity. As part of the deal, Novo Nordisk will buy three of Catalent's fill-finish facilities from Novo Holdings for USD 11 billion in cash. These facilities are dedicated to sterile drug filling and are anticipated to strengthen Novo Nordisk's production network for existing and future diabetes and obesity treatments. The acquisition will boost Novo Nordisk's filling capacity from 2026 onwards step by step.
In summary, the generic sterile injectables industry is developing at a fast pace, with recent advancements in innovation and technology being the key drivers of the industry's future. Through sound investment in R&D, automation, and drug delivery systems, pharmaceutical companies are poised to achieve success in an industry that competes fiercely. Through the execution of key strategies based on maintaining control over cost, diversification of products, and anticipating the need for adaptation in regulatory systems, pharmaceuticals will be assured of sustained success and growth with the market predicted to grow at a 10.5% CAGR.
The generic sterile injectables industry is developing at a rapid pace, being influenced by several factors like soaring demand for cheap healthcare solutions, improvements in production technologies, and regulatory reforms. As per Coherent Market Insights (CMI), the generic sterile injectables industry is expected to grow at a 10.5% CAGR over the forecast period, with the market size reaching US$ 93.39 billion by 2032.
With the growth of the industry, companies are constantly keeping an eye on technological advancements that enable them to remain competitive, comply with regulatory needs, and address evolving patient demands.
One of the most notable recent trends in the industry is the incorporation of innovation and technology into the production process. Automation has emerged as a central figure in maximizing production efficiency and consistency. Automated systems assist in streamlining processes, minimizing human errors, and making sterile injectables under the best quality standards. This transition is important for enhancing manufacturing speed and scalability, particularly in a market experiencing an increase in demand for generic injectables. Automation enables firms to handle the issues of high-volume manufacturing more effectively while providing the needed sterility and quality.
Source:
Companies: Armein Pharmaceuticals Pvt. Ltd.
Government Agency: National Institutes of Health.
